Correlation of matrix metalloproteinases and their inhibitors with hypoxia and angiogenesis in premenopausal patients with adenocarcinoma of the breast

Clinical Biochemistry

Volumn 44, Issue 12, 2011, Pages 969-974

  Vinothini, Govindarajah ^a   Aravindraja, Chairmandurai ^a   Chitrathara, K ^b   Nagini, Siddavaram ^a  

^a ANNAMALAI UNIVERSITY   (India)

^b Wel Care Hospital   (India)

Author keywords

Angiogenesis; Breast cancer; HIF1 ; Invasion; MMP; Premenopausal; RECK; TIMP 2; VEGF

Indexed keywords

GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; ANOXIA; BREAST NEOPLASMS; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREMENOPAUSE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960339589     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.05.010     Document Type: Article

References (43)

1. Yeole B.B. Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. Asian Pac J Cancer Prev 2008, 9:119-122.
2. Rao R.S., Nair S., Nair N.S., Kamath V.G. Acceptability and effectiveness of a breast health awareness programme for rural women in India. Indian J Med Sci 2005, 59:398-402.
3. Agarwal G., Pradeep P.V., Aggarwal V., Yip C.H., Cheung P.S. Spectrum of breast cancer in Asian women. World J Surg 2007, 31:1031-1040.
4. Guinebretìere J.M., Menet E., Tardivon A., Cherel P., Vanel D. Normal and pathological breast, the histological basis. Eur J Radiol 2005, 54:6-14.
5. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
6. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005, 87:287-297.
7. Brew K., Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010, 1803:55-71.
8. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., Nishimura S., Imamura Y., Kitayama H., Alexander D.B., Ide C., Horan T.P., Arakawa T., Yoshida H., Nishikawa S., Itoh Y., Seiki M., Itohara S., Takahashi C., Noda M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800.
9. Noda M., Takahashi C. Recklessness as a hallmark of aggressive cancer. Cancer Sci 2007, 98:1659-1665.
10. Noda M. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastat Rev 2003, 22:167-175.
11. Lee K.J., Lee K.Y., Lee Y.M. Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1? to reverse HRE site in the promoter. Biochim Biophys Acta 2010, 1803:608-616.
12. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
13. Jr Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007, 62:179-213.
14. Nieves B.J., D'Amore P.A., Bryan B.A. The function of vascular endothelial growth factor. Biofactors 2009, 35:332-337.
15. Agarwal G., Ramakant P., Forgach E.R., Rendón J.C., Chaparro J.M., Basurto C.S., Margaritoni M. Breast cancer care in developing countries. World J Surg 2009, 33:2069-2076.
16. Vinothini G., Nagini S. Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NF?B signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast. Clin Chim Acta 2010, 411:368-374.
17. Vinothini G., Senthil Murugan R., Nagini S. Mitochondria-mediated apoptosis in patients with adenocarcinoma of the breast: correlation with histological grade and menopausal status. Breast 2011, 20:86-92.
18. Elston C.W., Ellis I.O. Assessment of histological grade. The breast 1998, 356-384. New York, Edinburgh. C.W. Elston, O. Ellis (Eds.).
19. Nikane P.K., Pierce G.B. Enzyme-labeled antibodies: preparation and application for the localization of antigens. J Histochem Cytochem 1966, 14:929-931.
20. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
22. Liu S.C., Yang S.F., Yeh K.T., Yeh C.M., Chiou H.L., Lee C.Y., Chou M.C., Hsieh Y.S. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta 2006, 37:92-96.
23. Rahko E., Kauppila S., Pääkkö P., Blanco G., Apaja-Sarkkinen M., Talvensaari-Mattila A., Turpeenniemi-Hujanen T., Jukkola A. Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue-strong expression in intraductal carcinomas of the breast. Tumour Biol 2009, 30:257-264.
24. Talvensaari-Mattila A., Pääkkö P., Höyhtyä M., Blanco-Sequeiros G., Turpeenniemi-Hujanen T. MMP-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 1998, 83:1153-1162.
25. Hirvonen R., Talvensaari-mattila A., Pääkkö P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T1-2N0 breast carcinoma. Breast Cancer Res Treat 2003, 77:85-91.
26. Feng Y., Sun B., Li X., Zhang L., Niu Y., Xiao C., Ning L., Fang Z., Wang Y., Zhang L., Cheng J., Zhang W., Hao X. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat 2006, 103:319-329.
27. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
28. Vagzdys S., Lesauskaite V., Pangonyte D., Saladzinskas Z., Tamelis A., Pavalkis D. Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma, S. J Exp Med 2011, 223:67-73.
29. Kushlinsky N.E., Solovyov Y.N., Babkina I.V., Gershtein E.S., Bulicheva I.V. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors. Bull Exp Biol Med 2010, 149:233-235.
30. Daniele A., Zito A.F., Giannelli G., Divella R., Asselti M., Mazzocca A., Paradiso A., Quaranta M. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res 2010, 30:3521-3527.
31. Remacle A., McCarthy K., Noël A., Maguire T., McDermott E., O'Higgins N., Foidart J.M., Duffy M.J. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000, 89:118-121.
32. Visscher D.W., Höyhtyä M., Ottosen S.K., Liang C.M., Sarbar F.H., Crissman J.D., Fridman R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994, 59:339-344.
33. Kuvaja P., Talvensaari-Mattila A., Pääkkö P., Turpeenniemi-Hujanen T. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1) but not for TIMP-2 protein is associated with a favourable prognosis in aggressive breast carcinoma. Oncology 2005, 68:196-203.
34. Gonzalez L.O., Junquera S., del Casar J.M., González L., Marín L., González-Reyes S., Andicoechea A., González-Fernández R., González J.M., Pérez-Fernández R., Vizoso F.J. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. Hum Pathol 2010, 41:980-989.
35. Clark J.C., Thomas D.M., Choong P.F., Dass C.R. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007, 26:675-683.
36. Namwat N., Puetkasichonpasutha J., Loilome W., Yongvanit P., Techasen A., Puapairoj A., Sripa B., Tassaneeyakul W., Khuntikeo N., Wongkham S. Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. J Gastroenterol 2011, 46:664-675.
37. Xu J., Wu S., Shi X. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res 2010, 28:1621-1625.
38. Span P.N., Sweep C.G., Manders P., Beex L.V., Leppert D., Lindberg R.L. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 2003, 97:2710-2715.
39. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16:5928-5935.
40. Yamamoto Y., Ibusuki M., Okumura Y., Kawasoe T., Kai K., Iyama K., Iwase H. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008, 110:465-475.
41. Khosravi Shahi P., Soria Lovelle A., Pérez Manga G. Tumoral angiogenesis and breast cancer. Clin Transl Oncol 2009, 11:138-142.
42. Delli Carpini J., Karam A.K., Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010, 13:43-58.
43. M.S. Moran, Q. Yang, S. Goyal, L. Harris, G. Chung, B.G. Haffty, Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy, Int. J. Radiat. Oncol. Biol. Phys (in press).